Insmed Inc. (INSM)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$108.76-1.13%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · INSM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -31.3% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 79.9% |
Growth built into the price is above our model estimate.
The price assumes 111.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 65 industry peers · Company calendar date is not available
INSM — earnings miss
Dated 2026-10-29
The slide presentation to be used during the conference call referenced in the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference. The information contained herein, including the exhibits attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth b…
Why it matters: The FDA review may expand ARIKAYCE use for MAC lung disease. A delay or rejection would block this step.
Watch forThe FDA approves the ARIKAYCE label change by January 28, 2027.
Also watch forThe FDA rejects the label change or does not act by January 28, 2027.
Why it matters: Sara Bonstein left the CFO role on October 30, 2026. A named successor would close a key leadership gap.
Supportive ifInsmed names a new CFO in a company announcement or filing.
Worry ifInsmed reports that the CFO search is still open at its next earnings update.
Why it matters: U.S. sales grew only 2% year over year in Q3, while overseas sales drove most growth. Falling short would weaken the growth case.
Worry if2026 ARIKAYCE revenue is below $460 million for the full year.
Less concerning ifFull-year 2026 ARIKAYCE revenue reaches at least $460 million.
Why it matters: BRINSUPRI is Insmed's main growth driver. Revenue below the new floor would weaken the launch story.
Worry if2026 BRINSUPRI revenue is below $1.35 billion for the full year.
Less concerning ifFull-year 2026 BRINSUPRI revenue reaches at least $1.35 billion.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$163 on $10,000 · ±1.6% | How much price usually moves either way. |
| Bad day | $458 loss on $10,000 · 4.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,654 loss on $10,000 · 56.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: TPIP is a large Phase 3 program, but its trials are still underway. Faster enrollment would mark progress toward the planned 2028 finish.
Supportive ifInsmed reports PALM-ILD enrollment above 50% before the end of 2027.
Worry ifPALM-ILD enrollment remains at or below 35% by the end of 2027, or the planned first-half 2028 finish moves later.